Tenofovir amibufenamide

Modify Date: 2025-08-25 18:36:18

Tenofovir amibufenamide structure	Common Name	Tenofovir amibufenamide
	CAS Number	1571076-26-0	Molecular Weight	490.49
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₂H₃₁N₆O₅P	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Tenofovir amibufenamide

Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study[1][2].

Name	Tenofovir amibufenamide

Description	Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> HBV
References	[1]. Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149. [2]. Hong Zhang, et al. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021 Jan;53(2):243-252.

Description

Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study[1][2].

Related Catalog

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> HBV

References

[1]. Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149.

[2]. Hong Zhang, et al. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021 Jan;53(2):243-252.